Skip to content
EntityQ4712362· pop 5· linked from 148 articles

albiglutide

Sign in to save

Also known as GSK716155

Albiglutide (trade names Eperzan in Europe and Tanzeum in the US) is a glucagon-like peptide-1 agonist (GLP-1 agonist) drug marketed by GlaxoSmithKline (GSK) for treatment of type 2 diabetes. In 2017 GSK announced Albiglutide's withdrawal from the worldwide market for economic reasons, and remaining stocks in the supply chain were effectively depleted by 2018.

Chemical data

Drug data · ChEMBL

Max clinical phase
Approved
Molecule type
Protein
First approval
2014
Admin. routes
parenteral
Indications
congestive heart failure, diabetes mellitus, type 1 diabetes mellitus, type 2 diabetes mellitus

via ChEMBL · EBI

Wikidata facts

Has use
medication
Show 5 more facts
NCI Thesaurus ID
C78128
subject has role
incretins
medical condition treated
glucose intolerance
defined daily dose
5.7
has characteristic
biopharmaceutical
Sources (4)

via Wikidata · CC0

~6 min read

Encyclopedic overview

11 sections
Contents
  • Medical uses
  • Contraindications
  • Side effects
  • Interactions
  • Pharmacology
  • Mechanism of action
  • Pharmacokinetics
  • Chemistry
  • Synthesis
  • History
  • References

Albiglutide (trade names Eperzan in Europe and Tanzeum in the US) is a glucagon-like peptide-1 agonist (GLP-1 agonist) drug marketed by GlaxoSmithKline (GSK) for treatment of type 2 diabetes. In 2017 GSK announced Albiglutide's withdrawal from the worldwide market for economic reasons, and remaining stocks in the supply chain were effectively depleted by 2018.

==Medical uses== Albiglutide was used for the treatment of type 2 diabetes in adults. It can be used alone (if metformin therapy is ineffective or not tolerated) or in combination with other antidiabetic drugs, including insulins.

Excerpted from Wikipedia’s “albiglutide” article, available under the CC BY-SA 4.0 licence.

Available in 5 languages

via Wikidata sitelinks · CC0